Similar articles

• Immune intervention with anti-CD3 in diabetes.

  Harlan DM, von Herrath M. Harlan DM, et al. Nat Med. 2005 Jul;11(7):716-8. doi: 10.1038/nm0705-716. Nat Med. 2005. PMID: 16015359 No abstract available.
• Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.

  You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. You S, et al. Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6335-40. doi: 10.1073/pnas.0701171104. Epub 2007 Mar 26. Proc Natl Acad Sci U S A. 2007. PMID: 17389382 Free PMC article.
• Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.

  Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL. Ishikawa H, et al. Diabetes. 2007 Aug;56(8):2103-9. doi: 10.2337/db06-1632. Epub 2007 Apr 24. Diabetes. 2007. PMID: 17456848
• [Application of ATG, anti-CD3, anti-CD52 and anti-CD20 antibodies to transplantation].

  Sołdacki D, Mucha K. Sołdacki D, et al. Pol Arch Med Wewn. 2006 Feb;115(2):163-71. Pol Arch Med Wewn. 2006. PMID: 17274474 Review. Polish. No abstract available.
• CD3-specific antibodies: a portal to the treatment of autoimmunity.

  Chatenoud L, Bluestone JA. Chatenoud L, et al. Nat Rev Immunol. 2007 Aug;7(8):622-32. doi: 10.1038/nri2134. Epub 2007 Jul 20. Nat Rev Immunol. 2007. PMID: 17641665 Review.